guest ::
| Home > Publications database > Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival. > print |
| Home > Publications database > Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival. > print |
| 001 | 301762 | ||
| 005 | 20250608020943.0 | ||
| 024 | 7 | _ | |a 10.1038/s41467-025-59612-6 |2 doi |
| 024 | 7 | _ | |a pmid:40461501 |2 pmid |
| 024 | 7 | _ | |a altmetric:177712084 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01142 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 500 |
| 100 | 1 | _ | |a Talbot, Julie |b 0 |
| 245 | _ | _ | |a Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival. |
| 260 | _ | _ | |a [London] |c 2025 |b Springer Nature |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1749042714_17383 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Netrin-1 signaling is an essential prototypical neuronal guidance mechanism during embryonic development that also regulates tumor cell survival in a variety of adult cancer entities. In line with these data, a monoclonal netrin-1 blocking antibody (anti-netrin-1 mAb/NP137) has been preclinically developed and netrin-1 blockade has recently been investigated in phase 1 and 2 clinical trials in several adult cancers. Here, we investigate the role of netrin-1 in the most common malignant pediatric brain cancer, Medulloblastoma. Interestingly, we find that netrin-1 is upregulated in medulloblastoma subgroups associated with developmental dysregulation, in particular in medulloblastoma with Sonic Hedgehog (SHH) activation. First, we demonstrate that genetic deletion of netrin-1 or systemic treatment with the clinical-stage anti-netrin-1 blocking antibody significantly reduces tumor growth in vivo in various orthotopic models of SHH medulloblastomas. Second, in vitro and in vivo, we unexpectedly uncover that SHH medulloblastomas treated with an SHH-inhibitor targeting Smoothened (SMO) increase netrin-1 expression, paving the way for combinatorial therapy. In line with that, we next show that netrin-1 blockade potentiates the efficacy of SMO inhibitor therapy in vivo. Together, our data indicate that, netrin-1 blockade, used as monotherapy or in combination with SMO inhibitors, is a promising therapeutic strategy in SHH medulloblastomas. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Netrin-1 |0 158651-98-0 |2 NLM Chemicals |
| 650 | _ | 7 | |a Hedgehog Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a NTN1 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Smoothened Receptor |2 NLM Chemicals |
| 650 | _ | 7 | |a Ntn1 protein, mouse |2 NLM Chemicals |
| 650 | _ | 7 | |a Tumor Suppressor Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a SHH protein, human |2 NLM Chemicals |
| 650 | _ | 2 | |a Netrin-1: metabolism |2 MeSH |
| 650 | _ | 2 | |a Netrin-1: genetics |2 MeSH |
| 650 | _ | 2 | |a Netrin-1: antagonists & inhibitors |2 MeSH |
| 650 | _ | 2 | |a Medulloblastoma: metabolism |2 MeSH |
| 650 | _ | 2 | |a Medulloblastoma: genetics |2 MeSH |
| 650 | _ | 2 | |a Medulloblastoma: pathology |2 MeSH |
| 650 | _ | 2 | |a Medulloblastoma: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Hedgehog Proteins: metabolism |2 MeSH |
| 650 | _ | 2 | |a Hedgehog Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Cell Line, Tumor |2 MeSH |
| 650 | _ | 2 | |a Smoothened Receptor: antagonists & inhibitors |2 MeSH |
| 650 | _ | 2 | |a Smoothened Receptor: metabolism |2 MeSH |
| 650 | _ | 2 | |a Cerebellar Neoplasms: metabolism |2 MeSH |
| 650 | _ | 2 | |a Cerebellar Neoplasms: genetics |2 MeSH |
| 650 | _ | 2 | |a Cerebellar Neoplasms: pathology |2 MeSH |
| 650 | _ | 2 | |a Cerebellar Neoplasms: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Signal Transduction |2 MeSH |
| 650 | _ | 2 | |a Cell Survival: drug effects |2 MeSH |
| 650 | _ | 2 | |a Tumor Suppressor Proteins: metabolism |2 MeSH |
| 650 | _ | 2 | |a Tumor Suppressor Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Gene Expression Regulation, Neoplastic |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 700 | 1 | _ | |a Fombonne, Joanna |b 1 |
| 700 | 1 | _ | |a Torrejon, Jacob |b 2 |
| 700 | 1 | _ | |a Babcock, Benjamin R |0 0000-0002-2902-8045 |b 3 |
| 700 | 1 | _ | |a McSwain, Leon F |b 4 |
| 700 | 1 | _ | |a Rama, Nicolas |0 0000-0003-1614-7755 |b 5 |
| 700 | 1 | _ | |a Lospinoso Severini, Ludovica |b 6 |
| 700 | 1 | _ | |a Bonerandi, Emma |b 7 |
| 700 | 1 | _ | |a Marsaud, Veronique |b 8 |
| 700 | 1 | _ | |a Bernardi, Flavia |0 0000-0002-9740-2983 |b 9 |
| 700 | 1 | _ | |a Gharsalli, Tarek |b 10 |
| 700 | 1 | _ | |a Guix, Catherine |b 11 |
| 700 | 1 | _ | |a Ducarouge, Benjamin |0 0000-0002-6701-0508 |b 12 |
| 700 | 1 | _ | |a Neururer, Verena |b 13 |
| 700 | 1 | _ | |a Basili, Irene |0 0000-0002-5117-2529 |b 14 |
| 700 | 1 | _ | |a Mercier, Audrey L |b 15 |
| 700 | 1 | _ | |a Yu, Hua |0 0009-0001-6923-9111 |b 16 |
| 700 | 1 | _ | |a Forget, Antoine |b 17 |
| 700 | 1 | _ | |a Indersie, Emilie |0 0000-0001-8974-6551 |b 18 |
| 700 | 1 | _ | |a Leboucher, Sophie |0 0000-0001-9922-8205 |b 19 |
| 700 | 1 | _ | |a Souphron, Judith |b 20 |
| 700 | 1 | _ | |a Okonechnikov, Konstantin |0 P:(DE-He78)34b3639de467b2c700920d7cbc3d2110 |b 21 |u dkfz |
| 700 | 1 | _ | |a Wang, Wanchen |0 0000-0002-4098-7482 |b 22 |
| 700 | 1 | _ | |a Kawauchi, Daisuke |b 23 |
| 700 | 1 | _ | |a Wainwright, Brandon J |b 24 |
| 700 | 1 | _ | |a Frappaz, Didier |b 25 |
| 700 | 1 | _ | |a Varlet, Pascale |b 26 |
| 700 | 1 | _ | |a Dufour, Christelle |0 0000-0001-5993-8077 |b 27 |
| 700 | 1 | _ | |a Beccaria, Kevin |b 28 |
| 700 | 1 | _ | |a Blauwblomme, Thomas |0 0000-0003-4076-9642 |b 29 |
| 700 | 1 | _ | |a Martignetti, Loredana |0 0000-0003-1535-7515 |b 30 |
| 700 | 1 | _ | |a Di Marcotullio, Lucia |0 0000-0003-0274-7178 |b 31 |
| 700 | 1 | _ | |a Puget, Stéphanie |b 32 |
| 700 | 1 | _ | |a Doz, François |b 33 |
| 700 | 1 | _ | |a Bourdeaut, Franck |0 0000-0001-9489-6781 |b 34 |
| 700 | 1 | _ | |a Masliah-Planchon, Julien |b 35 |
| 700 | 1 | _ | |a Gershon, Timothy R |0 0000-0001-7034-6400 |b 36 |
| 700 | 1 | _ | |a Mehlen, Patrick |0 0000-0003-1743-5417 |b 37 |
| 700 | 1 | _ | |a Ayrault, Olivier |0 0000-0002-7942-6674 |b 38 |
| 773 | _ | _ | |a 10.1038/s41467-025-59612-6 |g Vol. 16, no. 1, p. 5137 |0 PERI:(DE-600)2553671-0 |n 1 |p 5137 |t Nature Communications |v 16 |y 2025 |x 2041-1723 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:301762 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)34b3639de467b2c700920d7cbc3d2110 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT COMMUN : 2022 |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-01-30T07:48:07Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-01-30T07:48:07Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2024-01-30T07:48:07Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2024-01-30T07:48:07Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1060 |2 StatID |b Current Contents - Agriculture, Biology and Environmental Sciences |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-02 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NAT COMMUN : 2022 |d 2025-01-02 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2025-01-02 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2025-01-02 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|